Shopping Cart
Remove All
Your shopping cart is currently empty
Bryonolic acid
Copy Product Info
😃Good
Catalog No. T19882Cas No. 24480-45-3
Alias UNII-J7YR6A878I, 20-epi-Bryonolic acid
Bryonolic acid (20-epi-Bryonolic acid), a triterpenoid extracted from Sandoricum indicum, possesses immunomodulatory, anti-inflammatory, antioxidant and anticancer activities and protects PC12 cells from NMDA-induced apoptosis by inhibiting Ca2+ in-flux and modulating gene expression in the Ca2+-CaMKII-CREB signalling pathway.
Bryonolic acid
Copy Product Info😃Good
Purity: 99.93%
Catalog No. T19882Alias UNII-J7YR6A878I, 20-epi-Bryonolic acidCas No. 24480-45-3
Bryonolic acid (20-epi-Bryonolic acid), a triterpenoid extracted from Sandoricum indicum, possesses immunomodulatory, anti-inflammatory, antioxidant and anticancer activities and protects PC12 cells from NMDA-induced apoptosis by inhibiting Ca2+ in-flux and modulating gene expression in the Ca2+-CaMKII-CREB signalling pathway.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $316 | - | In Stock | |
| 5 mg | $769 | - | In Stock | |
| 10 mg | $1,080 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.93%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Bryonolic acid (20-epi-Bryonolic acid), a triterpenoid extracted from Sandoricum indicum, possesses immunomodulatory, anti-inflammatory, antioxidant and anticancer activities and protects PC12 cells from NMDA-induced apoptosis by inhibiting Ca2+ in-flux and modulating gene expression in the Ca2+-CaMKII-CREB signalling pathway. |
| Targets&IC50 | M1 mAChR:7.08 (pKi), H1 Receptor:7.48 (pA2), M2 mAChR:7.78 (pKi), M4 mAChR:7.00 (pKi), M3 mAChR:6.70 (pKi) |
| In vitro | In the presence of three elicitors (methyl jasmonate, yeast extract, and chitosan), cell suspensions treated with 1 mg/mL of chitosan for eight days led to higher bryonolic acid contents (23.56 ± 1.68 mg/g dry weight),cell culture and root extracts with high bryonolic acid contents resulted in significantly higher percent cell viabilities than those observed under control (1% v/v DMSO) treatment in Saos-2 and MCF-7 cells[1]. Bryonolic acid inhibits ACAT in intact cancer cells with an IC50 of 12.6 ± 2.4 µM.Bryonolic acid inhibited both clonogenicity and invasiveness of several cancer cell lines[2]. |
| In vivo | Treatment with 500 mg/kg Bryonolic acid or vehicle by intraperitoneal injection in Nrf2 wild-type or Nrf2 knockout mice revealed that Bryonolic acid effectively induced HO-1 in a manner dependent on the Nrf2-Keap1 pathway[3]. |
| Synonyms | UNII-J7YR6A878I, 20-epi-Bryonolic acid |
| Molecular Weight | 456.7 |
| Formula | C30H48O3 |
| Cas No. | 24480-45-3 |
| Smiles | C[C@@]12[C@](C)([C@]3([C@@](C)(CC1)CC[C@@](C(O)=O)(C)C3)[H])CCC4=C2CC[C@@]5([C@]4(C)CC[C@H](O)C5(C)C)[H] |
| Relative Density. | 1.10 g/cm3 (Predicted) |
| Storage | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | DMSO: 1 mg/mL (2.19 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
DMSO
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Bryonolic acid | purchase Bryonolic acid | Bryonolic acid cost | order Bryonolic acid | Bryonolic acid chemical structure | Bryonolic acid in vivo | Bryonolic acid in vitro | Bryonolic acid formula | Bryonolic acid molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.